RxDoctor Payments DataLook up a doctor →

Sandeep Mann, MD

Internal Medicine · Dover, DENPI 1891776761

Payments from drug & device makers

$6,089in general payments, 2019–2025

Across 361 payments — averaging $16.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$916
  • Pfizer$781
  • AstraZeneca$533
  • Lilly USA, LLC$446
  • Astellas Pharma US Inc$401
  • Amgen$383
  • plus $3K from 37 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk65$916
Pfizer45$781
AstraZeneca29$533
Lilly USA, LLC27$446
Astellas Pharma US Inc22$401
Amgen25$383
AbbVie(2 entities)18$357
Johnson & Johnson9$199
Dexcom, Inc.9$161
Boehringer Ingelheim11$157
Abbott8$152
Novartis10$146
Merck9$137
GSK8$130
Sanofi-aventis U.S. LLC7$120
Shield Therapeutics Inc3$106
Bayer4$75
Amarin Pharma, Inc.5$71
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC4$65
Medtronic3$64
Phathom Pharmaceuticals, Inc.4$59
Teva Pharmaceuticals USA, Inc.4$53
Viiv Healthcare Company2$50
Xeris Pharmaceuticals, Inc.3$50
Exact Sciences2$49
E.r. Squibb & Sons, L.L.C.2$43
Alkermes, Inc.3$42
Kowa Pharmaceuticals America, Inc.2$42
Sanofi Pasteur Inc.2$38
Mannkind Corporation2$31
Seqirus USA Inc2$31
Genentech USA, Inc.1$21
Bristol Myers Squibb1$21
Krystal Biotech Inc1$19
Insulet Corporation1$19
Verona Pharma, Inc.1$18
Mylan Specialty L.p.1$17
Eisai Inc.1$17
Currax Pharmaceuticals LLC1$16
Watermark Medical, Inc.1$16
Nestle Healthcare Nutrition Inc.1$15
Esperion Therapeutics, Inc.1$11
Intra-sana Laboratories1$9

How this compares

$6,089 in reported general payments places this provider in the 90th percentile of 477 internal medicine providers in Delaware.

See all internal medicine providers in Delaware →

Medicare billing

Part B allowed, 2024
$142,492
Medicare patients
629
Services billed
2,764

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Dover

See the full list for Delaware →

Where these figures come from

Is this you, or does something look wrong? →